0
Strongbridge Biopharma plc Banner Image

Strongbridge Biopharma plc has reached its limit for free report views

Work for Strongbridge Biopharma plc? Upgrade Your Profile and unlock all your annual reports.

Strongbridge Biopharma plc

  • Ticker SBBP
    Exchange NASDAQ More
  • Industry Biotechnology More
  • Sector Healthcare More
Strongbridge Biopharma plc Logo Image
  • 51-200 Employees
  • Based in Trevose, Pennsylvania
Strongbridge Biopharma is a global commercial-stage biopharmaceutical company focused on the development and commercialization of therapies for rare diseases with significant unmet needs. Strongbridge’s commercial portfolio within its rare endocrine franchise includes RECORLEV™ (levoketoconazole), a cortisol synthesis inhibitor currently being studied in Phase 3 clinical studies for theMore treatment of endogenous Cushing’s syndrome, and veldoreotide extended release, a pre-clinical next-generation somatostatin analog being investigated for the treatment of acromegaly and potential additional applications in other conditions amenable to somatostatin receptor activation. Both RECORLEV and veldoreotide have received orphan drug designation from the FDA and the European Medicines Agency. The Company’s rare neuromuscular franchise includes KEVEYIS® (dichlorphenamide), the first and only FDA-approved treatment for hyperkalemic, hypokalemic, and related variants of primary periodic paralysis. KEVEYIS has orphan drug exclusivity in the United States.
Strongbridge Biopharma plc

Most Recent Annual Report

Strongbridge Biopharma plc MOST RECENT 2020 Annual Report

Report Locked. Strongbridge Biopharma plc has reached its limit for free report views.

Older/Archived Annual Reports